Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two related deaths, according to the FDA and CDC.

A landmark global modeling study reveals that more than 2.8 billion people in 104 countries are at risk of chikungunya, with ...

Federal drug safety officials have recommended pausing the use of a vaccine ... of chikungunya disease. The FDA said it will conduct an updated benefit-risk assessment for the use of Ixchiq ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

With this extension, IXCHIQ ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU).

The UK’s Medicines and Healthcare products Regulatory Agency said that following global reports of serious adverse events in ...

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set ...

have advised a temporary halt in administering the chikungunya vaccine Valneva SE’s VALN Ixchiq to adults aged 60 and older as they investigate reports of serious adverse events, including ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...